An Introduction to Parkinson's Disease
Parkinson’s disease (PD), the most common movement disorder, is characterized by dopamine deficiency and motor symptoms, such as tremor, rigidity, bradykinesia and impaired balance; non-motor symptoms are increasingly being recognized as important too. Despite advances in our understanding of PD by functional genetics, brain imaging and biomarker detection, it remains incurable. While levodopa remains the mainstay of therapy, other treatments include levodopa plus carbidopa (oral/gel infusion), dopamine agonists, MAO-B and COMT inhibitors, anticholinergics and amantadine. Latest approvals include opicapone, a COMT inhibitor, and istradefylline, an adenosine A2A antagonist; both boost the effect of levodopa for better symptom control. Investigational approaches include disease-modifying therapies targeting α-synuclein and its pathways, immunotherapies, stem-cell therapy and non-pharmacological interventions targeting motor symptoms, including gene therapy and adaptive deep-brain stimulation.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Parkinson's Disease Content
Angelo Antonini, EAN 2023: Highlights in Parkinson’s disease
touchNEUROLOGY editorial board member Prof. Angelo Antonini (Padua University Hospital, Italy) provides an overview of his top three most important updates and hot topics from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of Parkinson’s disease. He particularly focusses on new insights in early detection of the disease before motor symptoms […]
Highlights from EAN 2023!
Wellness in Parkinson’s Disease: A Framework for Management Using a Holistic Culturally Sensitive Approach
touchREVIEWS in Neurology. 2023;19(1):8–13 DOI: https://doi.org/10.17925/USN.2023.19.1.8
In modern medicine, the concept of wellness is accompanied by many misconceptions. Adopting wellness as a treatment approach has been well defined and implemented in cardiovascular disease, diabetes and some types of cancer management but has not yet been widely applied to neurologic diseases.1–5 The commercialization of the wellness industry has led to the misconception of wellness as expensive and only accessible to a niche population […]
The place of on-demand therapy in the treatment of OFF episodes
Learn about the treatment paradigm for OFF and the place of on-demand therapy in it.
The impact of delayed ON: Treating OFF episodes in patients with Parkinson’s disease
Leading experts Stuart Isaacson MD, Yasar Torres-Yaghi MD, Rajesh Pahwa MD discuss how to reduce the impact of delayed ON in Parkinson’s disease
Veronica Clark, Parkinson’s Europe: Presidential Update, and the Parkinson’s Manifesto for Europe
The European Parkinson’s Disease Association (EPDA) recently changed its name to Parkinson’s Europe. They are the only European Parkinson’s umbrella organisation and have been working with the global Parkinson’s community for nearly 30 years. As a leading voice for Parkinson’s in Europe, they provide trusted information; advance and share good practices; raise awareness and improve […]
Suman Kushwaha, MDS 2022: COVID-19 vaccine induced parkinsonism and cognitive dysfunction
Two cases of COVID-19 vaccination associated neurological symptoms were presented, with patients displaying parkinsonism and cognitive dysfunction. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behaviour and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms and investigations leading to the case report conclusions. The abstract entitled […]
Suman Kushwaha, MDS 2022: Neurological symptoms and COVID-19 vaccination
Neurological complications, such as peripheral neuropathy, have been associated with COVID-19 vaccination. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behavior and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms that have been observed. The abstract entitled ‘Covid vaccine induced parkinsonism and cognitive dysfunction’ was presented […]
Angelo Antonini, EAN 2022: New therapies and optimal treatment approaches for Parkinson’s disease
Data emerging from upcoming clinical trials assessing the treatment efficacy in people with clinically established Parkinson’s disease will shed light on optimal treatment approaches. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) gives his thoughts on these and discusses how new efficacious therapies for Parkinson’s disease […]
Angelo Antonini, EAN 2022: Update on disease-modifying treatments in Parkinson’s disease
Slowing down the progression of Parkinson’s disease is key to improving outcomes. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) presents the core concept of the Movement Disorders Society Task Force on the biological definition of Parkinson’s disease and treatment objectives, and shares his thoughts on […]
Heinz Reichmann, EAN 2022: Highlights in Parkinson’s disease
In an interview with touchNEUROLOGY, Prof. Heinz Reichmann (University of Dresden Medical School, Germany) gave us his insight into his highlights in Parkinson’s disease, the interventions currently under investigation and how he sees management strategies for Parkinson’s disease evolving in the coming years. Questions: What are your highlights from the Parkinson’s disease scientific sessions at […]
Ray Chaudhuri, EAN 2022: Update on opicapone for Parkinson’s disease
Opicapone has proved effective for the treatment of end-of-dose motor fluctuations in patients with Parkinson’s disease. Here, Prof. Ray Chaudhuri (King’s College Hospital, London, UK) discusses the effect of disabling fluctuations and dyskinesias on patient quality of life, efficacy and safety of opicapone, and the best way to incorporate this treatment into practice. Questions: For […]
Tiago Outiero, EAN 2022: Biological versus clinical diagnosis of Parkinson’s disease
Early detection of Parkinson’s disease can vastly improve outcomes. Prof. Tiago Outiero (University Medical Center Goettingen, Goettingen, Germany) discussed with touchNEUROLOGY his research combining basic science to use biological markers and clinical signs to diagnose Parkinson’s disease. Questions: Why is early detection of Parkinson’s disease essential, and what are the current challenges in achieving this? […]
Amantadine extended release for treatment of dyskinesia and OFF episodes
Understand how amantadine extended release represents a significant advance in the treatment of dyskinesia and OFF in Parkinson’s disease
Directional Deep Brain Stimulation in the Treatment of Parkinson’s Disease
touchREVIEWS in Neurology. 2022;17(2):64–7 DOI: https://doi.org/10.17925/USN.2022.18.1.64
Deep brain stimulation (DBS) is an effective treatment that significantly reduces disabling levodopa-induced motor complications (i.e. dyskinesia and motor fluctuations) and tremor in individuals with Parkinson’s disease (PD).1,2 During DBS, electrical stimulation is delivered through stereotactically implanted electrodes into one of two primary targets considered for PD: the subthalamic nucleus or the globus pallidus internus. The […]
The clinical evidence for opicapone across the duration of PD
Watch leading experts discuss the clinical evidence for opicapone across the duration of PD
UK Prescribing Information
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Angelo Antonini, AD/PD 2022: Key clinical highlights in movement disorders and Parkinson’s disease
Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses the key clinical highlights and hot topics in movement disorders and Parkinson’s disease. Questions: What are the key clinical highlights from the past year in the field of movement disorders and Parkinson’s disease? Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!